top of page

News

October 1, 2026

MavriX Bio Announces FDA Rare Pediatric Disease Designation for Investigational MVX-220 for the Treatment of Angelman Syndrome

November 6, 2025

MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome

September 22, 2025

MavriX Bio Receives FDA Fast Track Designation for MVX-220 for
Treatment of Angelman Syndrome

May 12, 2025

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome

V2-03.png
Bringing scientific breakthroughs for Angelman syndrome, from the lab to the clinic, and ultimately, to the individuals who need them most. 

To invest with us, or learn more, write to us at 

info@mvxbio.com

bottom of page